SION
HealthcareSionna Therapeutics, Inc. · Biotechnology · $2B
What is Sionna Therapeutics, Inc.?
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused exclusively on cystic fibrosis. Based in Waltham, Massachusetts, the company is working to develop medicines that address the underlying cause of the disease rather than just its symptoms.
Sionna Therapeutics targets the cystic fibrosis transmembrane conductance regulator — the protein whose malfunction drives cystic fibrosis. By developing compounds designed to normalize CFTR function, the company aims to shift how patients are treated at a biological level. As a clinical-stage company, Sionna does not yet generate product revenue; it funds operations through capital raises while advancing its pipeline toward clinical milestones.
Sionna Therapeutics was founded in 2025 and is headquartered in Waltham, Massachusetts.
- CFTR modulator drug candidates targeting cystic fibrosis
- Next-generation small-molecule therapies for CFTR normalization
- Clinical-stage pipeline focused on rare respiratory disease
Is SION a Good Stock to Buy?
UQS Score rates SION as Poor overall, reflecting early-stage development challenges across most quality dimensions.
The one area where SION shows relative resilience is Risk, which earns a Good label — suggesting the company's balance sheet or near-term solvency profile is not the primary concern at this stage. This is not uncommon for recently formed biotechs that have raised capital ahead of clinical spending.
Quality, Moat, and Growth all carry Weak labels, reflecting the absence of revenue, an unproven competitive position, and limited near-term catalysts. Valuation is rated Elevated, meaning the market is pricing in significant future success that has yet to be demonstrated.
Pro members can view the full pillar breakdown and underlying financial metrics to assess where SION stands relative to other small-cap biotechs. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SION pay dividends?
No — Sionna Therapeutics, Inc. does not currently pay a dividend.
Sionna Therapeutics does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward research, development, and advancing the pipeline toward regulatory milestones. Investors in SION are typically seeking potential long-term appreciation tied to clinical outcomes rather than income.
When does SION report earnings?
Sionna Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, Sionna's quarterly reports center on pipeline progress, cash runway, and operating expenses rather than product revenue. Investors should focus on R&D spend trends and any clinical update disclosures alongside financial filings.
For the most current quarterly results and pipeline updates, visit Sionna Therapeutics' investor relations page directly.
SION Price History
+203.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Sionna Therapeutics, Inc.?
Based on Sionna Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SION Long-term Outlook
With Growth and Quality both rated Weak, Sionna's near-term fundamental trajectory depends heavily on clinical trial outcomes rather than organic business expansion. The Good Risk label provides some reassurance that the company is not in immediate financial distress, but the Elevated Valuation label suggests the current market price already reflects optimistic assumptions about pipeline success. Progress in CFTR modulator development would be the primary catalyst for any re-rating.
Growth drivers
- Advancement of CFTR modulator candidates through clinical stages
- Potential for partnership or licensing deals with larger pharma companies
- Growing unmet need in cystic fibrosis treatment innovation
Key risks
- Clinical trial failure or delays could significantly impair value
- Elevated Valuation leaves little margin for setbacks
- Dependence on external capital with no current product revenue
SION vs Peers
Sionna operates in a competitive rare-disease and specialty biotech space alongside several other clinical and commercial-stage companies.
Trevi focuses on chronic pruritus and other neurologically driven conditions, pursuing a different rare-disease niche than Sionna's CFTR-centered approach.
AnaptysBio develops antibody-based therapies for inflammatory diseases, giving it a distinct mechanism and broader therapeutic focus compared to Sionna.
BioCryst has a commercial-stage rare-disease franchise, providing a revenue base that distinguishes it from Sionna's pre-revenue pipeline stage.
Frequently Asked Questions
What does Sionna Therapeutics do?
Sionna Therapeutics is a biopharmaceutical company developing medicines that target the cystic fibrosis transmembrane conductance regulator. Its goal is to normalize CFTR protein function in cystic fibrosis patients, addressing the root biological cause of the disease rather than managing symptoms alone.
Does SION pay dividends?
No, Sionna Therapeutics does not pay a dividend. As a clinical-stage company with no product revenue, it reinvests all capital into research and development. Dividend payments are not typical for early-stage biotechs at this point in their lifecycle.
When does SION report earnings?
Sionna Therapeutics follows a standard quarterly reporting schedule for US-listed companies. Because it is pre-revenue, reports focus on pipeline milestones and cash position rather than sales figures. Check the company's investor relations page for the latest filing dates.
Is SION a good stock to buy?
UQS Score rates SION as Poor overall. The Risk pillar earns a Good label, but Quality, Moat, and Growth are all Weak, and Valuation is Elevated. Whether SION fits a portfolio depends on an investor's risk tolerance and conviction in the clinical pipeline. The full pillar breakdown is available to Pro members.
Is SION overvalued?
The UQS Valuation pillar for SION is rated Elevated, suggesting the current market price reflects optimistic assumptions about future clinical success. For a pre-revenue biotech, valuation is inherently speculative and tied to pipeline outcomes rather than current earnings.
How does SION compare to its competitors?
Compared to peers like BioCryst Pharmaceuticals, which has commercial-stage revenue, Sionna is at an earlier development stage. Competitors such as AnaptysBio and Trevi Therapeutics pursue different disease areas, making direct comparisons complex. UQS Score provides side-by-side pillar comparisons for Pro members.
What is SION's market cap bracket?
Sionna Therapeutics is classified as a small-cap company. Small-cap biotechs typically carry higher volatility and binary risk tied to clinical events, which is reflected in SION's overall UQS profile.
Who founded Sionna Therapeutics?
Sionna Therapeutics was established in 2025. For detailed founding history and leadership background, the company's official website and SEC filings are the most reliable sources of information.
Is SION a long-term quality investment?
As a long-term quality indicator, SION's UQS Score of Poor — driven by Weak ratings across Quality, Moat, and Growth — signals meaningful uncertainty. The Good Risk label offers some near-term reassurance, but long-term quality depends on clinical execution and the ability to build durable competitive advantages over time.
What is the main competitive advantage of Sionna Therapeutics?
Sionna's focus is its specialized expertise in CFTR biology and cystic fibrosis drug development. However, the UQS Moat pillar is currently rated Weak, reflecting that the company has not yet established a proven, durable competitive position — a common characteristic of pre-commercial biotechs.
What sector does SION belong to?
Sionna Therapeutics operates in the Healthcare sector, specifically within biopharmaceuticals and rare-disease drug development. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) to see how SION compares across the sector.
Unlock Full SION Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare SION against peers on every quality dimension
- ✓See Valuation and Risk signals in full detail
- ✓Track score changes as new data becomes available
Pro Analysis
SION — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 12.7 | 0.0 | 9.0 | 0.0 | 69.5 | 0.0 | +0.1 |
| May 14, 2026 | 12.6 | 0.0 | 9.0 | 0.0 | 69.3 | 0.0 | +3.4 |
| May 9, 2026 | 9.2 | 0.0 | 9.0 | 0.0 | 46.2 | 0.0 | -3.4 |
| Apr 2, 2026 | 12.6 | 0.0 | 9.0 | 0.0 | 69.1 | 0.0 | — |
SION — Pillar Breakdown
Quality
— 0.0/100 (25%)Sionna Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Sionna Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.5/100 (15%)Sionna Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Sionna Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Sionna Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SION.
Score Composition
Financial Data
More Stock Analysis
How is the SION UQS Score Calculated?
The UQS (Unified Quality Score) for Sionna Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Sionna Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Sionna Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.